“The total lifetime value per genome using EDNA’s enhanced platform in a
free market would likely range between $200,000 to $500,000, with
Rare Datasets potentially exceeding $1 million.”
Conventional DNA testing services typically claim ownership of the genetic data, using opaque terms of service that benefit the companies rather than the individuals. EDNA’s approach, built on blockchain technology, ensures that users retain full ownership and control of their genetic information and that every transaction is transparent and secure.
Traditional genetic tests typically cover only a minuscule fraction of the genome (often less than 0.02%), which limits researchers’ ability to extract comprehensive insights for personalized medicine and advanced research. In contrast, EDNA’s advanced T2T reference genome sequencing leverages the first complete, gapless sequence of a human genom, providing a much richer and more reliable dataset.
Researchers today often face challenges sourcing high‑quality, ethically consented genetic data. Meanwhile, individuals contribute their genetic material without receiving fair compensation. EDNA’s model not only secures data with explicit user consent but also creates a marketplace where genetic data is treated as a valuable asset – allowing individuals to monetize their DNA and potentially generate significant returns.
High‑quality genome sequencing remains prohibitively expensive for many, particularly in underprivileged communities. EDNA’s collateral‑backed model helps democratize access to sequencing services, thereby enriching genetic datasets with more diverse and representative samples, which benefits both research and societal equity.
EDNA’s solution uniquely combines state‑of‑the‑art T2T whole genome sequencing, blockchain technology, AI‑driven genetic counseling, and a DeFi micro‑lending model – all in one platform.
EDNA offers a state-of-the-art 100% complete genome analysis that far exceeds traditional “neanderthal‐style” tests covering less than 0.02% of the genome.
By using blockchain and smart contracts, the platform gives users full control over their DNA – and the ability to profit from it with transparent, immutable transaction records creating a free market for a new asset class. US Patent Pending # 63/776,124
EDNA democratizes access to high‑quality and value-add sequencing by allowing underprivileged communities to borrow funds to get sequenced, linking financial returns with social impact.
The business model spans direct sequencing services, genetic counseling, data sales to researchers/biopharma, and other income channels that diversify risk and revenue.
EDNA operates in a booming market where individual genomes are valued at hundreds of thousands of dollars, making its high‑quality data an exceptionally valuable asset.
By “smashing poverty” through its inclusive financial model and ensuring underrepresented communities participate, EDNA appeals to investors focused on both returns and social good.
With operations not just domestically but also through EDNA Africa Pty. Ltd. and plans for further global expansion, the platform is built to scale across diverse markets.
The use of blockchain combined with advanced encryption protocols ensures that users’ genetic data is secure, private, and well‑protected from unauthorized access.
Greg Simpson Founder & CTO
